Yi-Hsiang Liu Selected Research

Dasatinib (BMS 354825)

1/2021

Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yi-Hsiang Liu Research Topics

Disease

19	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 01/2002
12	Neoplasms (Cancer) 01/2019 - 01/2002
7	Carcinogenesis 07/2017 - 01/2004
1	Infections 01/2018
1	Liver Neoplasms (Liver Cancer) 01/2018
1	Cholangiocarcinoma 01/2018
1	Fibrosarcoma 03/2015
1	Carcinoma (Carcinomatosis) 07/2008
1	Pain (Aches) 04/2006
1	Adenocarcinoma 01/2004
1	Adenoma (Adenomas) 01/2004

Drug/Important Bio-Agent (IBA)

10	PlectinIBA 01/2018 - 01/2004
5	Keratins (Keratin)IBA 01/2018 - 01/2002
5	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2002
4	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 01/2018
4	Histones (Histone)IBA 07/2017 - 01/2002
4	Keratin-18 (Keratin 18)IBA 07/2017 - 07/2008
3	desmuslin (synemin)IBA 01/2011 - 01/2004
2	Cadherins (E-Cadherin)IBA 01/2019 - 01/2018
2	Pharmaceutical PreparationsIBA 01/2018 - 01/2018
2	Histone Deacetylases (Histone Deacetylase)IBA 07/2017 - 03/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Dasatinib (BMS 354825)FDA Link 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2018
1	Histone Deacetylase 1IBA 03/2015
1	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2015
1	AluminumIBA 04/2006
1	GalliumIBA 04/2006

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2019
2	Lasers (Laser) 04/2006 - 01/2004
2	Low-Level Light Therapy (LLLT) 04/2006 - 01/2004
1	Subcutaneous Injections 01/2019
1	Minimally Invasive Surgical Procedures 09/2012